Drug repurposing for the treatment of staphylococcal infections.
Drug repurposing for the treatment of staphylococcal infections.
复制标题
DOI：
10.2174/1381612821666150310104416
复制
发表时间：
2015
影响因子：
3.1
通讯作者：
Seleem MN
中科院分区：
文献类型：
--
作者：
Thangamani S;Mohammad H;Younis W;Seleem MN
能够用于治疗由多重耐药病原体引起的感染的新抗菌剂的开发和批准没有跟上细菌耐药性的迅速出现。毫无疑问，有一个关键的未满足的需要，确定新的战略，开发抗菌剂，以应对这一新的祸害。一个值得特别关注的策略是药物再利用，这是识别新抗菌药物的独特方法。几种已批准的药物已成功地用于不同的疾病，这给人们带来了希望，这种策略也可以用来发现新的抗菌药物。为了帮助在这个过程中，目前的审查提出了批准的药物，已被证明具有抗金黄色葡萄球菌的抗菌活性及其潜在的临床应用。此外，还解释了具有新应用的批准药物，如干扰葡萄球菌发病机制和宿主免疫调节剂。目前的综述还讨论了与将已批准的药物重新用作抗菌药物相关的挑战，以及可进一步探索已批准药物的潜在用途，以开发这些现有药物作为治疗多重耐药葡萄球菌感染的新型疗法。总的来说，所提供的信息表明，将已批准的药物重新用作抗菌药物可能有助于加快药物开发过程，并节省多年来投资于抗菌药物开发的昂贵研究。
The development and approval of new antimicrobials capable of being used to treat infections caused by multidrug-resistant pathogens has not kept pace with the rapid emergence of bacterial resistance. Without a doubt, there is a critical unmet need for the identification of novel strategies to develop antimicrobials to deal with this new scourge. One strategy, which warrants special attention as a unique method for identifying new antimicrobials, is drug repurposing. Several approved drugs have been successfully repurposed for different ailments giving hope that this strategy can also be utilized to uncover new antibacterials. To aid in this process, the present review presents approved drugs, which have been shown to possess antimicrobial activity against Staphylococcus aureus and their potential clinical applications. Additionally, approved drugs with novel applications such as interference in staphylococcal pathogenesis and host immunomodulators are also explained. The current review also discusses the challenges associated with repurposing approved drugs as antibacterials and potential uses of approved drugs that can be further explored to develop these existing drugs as novel therapeutics to treat multi-drug resistant staphylococcal infections. Collectively, the information presented demonstrates that repurposing approved drugs as antimicrobials may help to speed up the drug development process and save years of expensive research invested in antimicrobial drug development.
登录
查看更多内容
影响因子：
3.5
作者：
Cassetta, Maria Iris;Marzo, Tiziano;Messori, Luigi
通讯作者：
Messori, Luigi
影响因子：
2.7
作者：
Chan, KY;Boucher, ES;Silva, MA
通讯作者：
Silva, MA
影响因子：
4.9
作者：
Aeschlimann, JR;Dresser, LD;Rybak, MJ
通讯作者：
Rybak, MJ
影响因子：
2
作者：
Burri, C;Brun, R
通讯作者：
Brun, R
DOI：
10.1161/01.atv.0000163840.63685.0c
发表时间：
2005-06-01
影响因子：
8.7
作者：
Arnaud, C;Burger, F;Mach, F
通讯作者：
Mach, F